Access
Bringing high-quality biological medicines within reach — for more patients, in more markets. Biosimilars are a structural pathway to broader access, not a compromise on quality.
01 / About BioXpress
A biosimilar engine
built on expertise.
BioXpress brings industrial biotechnology disciplines together to successfully develop complex biosimilar monoclonal antibodies.
Our purpose
We care about patients.
We care about our planet.
BioXpress is a Swiss Contract Research Organization (CRO) focused on biosimilar development, from cell-line design through regulatory filing. We believe high-quality biological medicines should be accessible to every patient and that responsible development is part of this commitment.
Our team has been deeply involved in the development of more than 12 originator biologics — including Herceptin®, Perjeta®, Rituxan®, Xolair®, Raptiva®, Kogenate®, Rebif® and Avastin® — and we bring this unique expertise to every BioXpress biosimilar programme.
The Biosimilar Engine
Innovation, quality
and cost efficiency.
BioXpress operates as a CRO for its own pipeline and for third parties, and manages cell-line development, analytical characterisation, manufacturing and regulatory activities. Our manufacturing approach is designed to deliver measurable time-to-market and cost advantages.
-
01
Cell-line
development -
02
Analytical
characterisation -
03
Process
development -
04
Manufacturing
strategy -
05
Clinical & regulatory
development
What guides us
Access, quality, efficacy,
sustainability and origin.
Quality
A quality-led approach from cell-line design through regulatory filing. Biosimilarity is demonstrated analytically, functionally, through PK/PD studies and clinically — quality is the foundation, not a feature.
Efficacy
Cost- and resource-aware manufacturing processes that deliver measurable time-to-market and cost advantages.
Sustainability
In all our developments, we care about reducing energy, water and CO₂ footprints.
Swiss base
BioXpress Therapeutics SA
Route de l’Île-au-Bois 1A
1870 Monthey, Switzerland
Biosimilars, simply explained
Highly similar.
Rigorously compared.
A biosimilar is developed by comparing it during all development steps with the already approved originator drug, called the reference medicine.
Highly similar
Its structure, biological activity and performance must be highly similar to those of the reference medicine.
No meaningful clinical difference
It must demonstrate no clinically meaningful differences in quality, safety or efficacy.
Designed to broaden access
Biosimilars can create additional treatment options and support wider access to biological medicines.
Not a simple generic copy.
Biological medicines are complex and produced using living systems. Demonstrating biosimilarity therefore requires extensive analytical, functional and clinical comparison.